Skip to main content

Scorpion Therapeutics Expands Executive Leadership Team With Three Key Appointments

– Kristin Schuhwerk joins as Chief Operating Officer –

 – Andrew Fedder joins as General Counsel –

 –  Adam Friedman, M.D., Ph.D. promoted to President, Corporate Strategy & Business Development –

BOSTON, Mass. – October 25, 2021 – Scorpion Therapeutics, Inc., a next-generation Oncology company whose goal is to develop best- and first-in-class precision medicines for cancer patients (“Scorpion”), today announced the executive appointments of Kristin Schuhwerk as Chief Operating Officer and Andrew Fedder as General Counsel, both joining as new hires, as well as the promotion of Adam Friedman, M.D., Ph.D to President, Corporate Strategy & Business Development, effective immediately.

“We are thrilled to welcome Kristin and Andrew to our leadership team,” said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion. “They each bring tremendous domain expertise, as well as proven leadership skills that will be invaluable as we continue to build Scorpion into a premier next-generation Oncology company. We eagerly anticipate their many contributions as we work together to execute Scorpion’s goal of delivering best- and first-in-class medicines to cancer patients.”

Dr. Hoos continued, “Adam’s promotion to President, Corporate Strategy & Business Development is well-deserved and reflects his many contributions to Scorpion, both in building our team and corporate culture and in advancing research and development efforts across our pre-clinical portfolio. I look forward to a continued partnership with Adam and new collaborations with Kristin and Andrew as we advance Precision Oncology 2.0, with the goal of delivering superior outcomes in Oncology.”

Kristin Schuhwerk, Chief Operating Officer

Ms. Schuhwerk brings over 25 years of leadership experience in pharmaceutical and biotechnology operations strategy and drug development, with particular expertise in project and portfolio management and clinical operations. Ms. Schuhwerk joins Scorpion from Sanofi, where she served most recently as Vice President and Global Head of Project & Portfolio Management, Development, with responsibility for overall management and delivery of the company’s development portfolio. Earlier, Ms. Schuhwerk held positions of increasing responsibility at Sanofi and gained a broad range of experience in both operations and oncology, including serving as Vice President and Global Head of Clinical Operations, where she oversaw over 300 clinical trials across more than 40 countries. She has a deep knowledge of start-up biotechnology operations, stemming from leadership and implementation roles at Moderna, Novelos Therapeutics, Antigenics, PHT Corporation and Astra Pharmaceuticals. Previously, Ms. Schuhwerk was a Project Director at the Brigham & Women’s Hospital Thrombolysis in Myocardial Infarction (TIMI) study group, an academic research organization dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease. She holds a B.S. in Chemistry from the University of New Hampshire.

Andrew Fedder, General Counsel

Mr. Fedder brings over a decade of legal experience to Scorpion. During the course of his career, he has advised on a wide array of complex business transactions in the pharmaceutical space, with a focus on acquisitions, divestitures and investments. Prior to joining Scorpion, Mr. Fedder worked at Bristol-Myers Squibb Company in increasing roles of responsibility, most recently acting as Assistant General Counsel for Corporate and Business Development and, previously, Senior Corporate Counsel for the company’s Mergers & Acquisitions team. Before Bristol-Myers Squibb Company, Mr. Fedder held positions at international law firms Willkie Farr & Gallagher and Wilson Sonsini Goodrich & Rosati, representing both public and private companies in the life sciences, technology and other industries in connection with mergers, acquisitions, investments, and governance and general corporate matters. Mr. Fedder holds a J.D. from Emory University School of Law and a B.A. in Economics from Johns Hopkins University.

Adam Friedman, M.D., Ph.D., President, Corporate Strategy & Business Development

Dr. Friedman is an accomplished physician, scientist and life sciences entrepreneur with extensive experience in oncology. Prior to his appointment as President, Corporate Strategy & Business Development, he served as the interim CEO of Scorpion. Before joining the company in 2020, Dr. Friedman served as Director at Serien Therapeutics, a next-generation immuno-metabolism company, and as President, Chief Executive Officer and founder of Vivid Biosciences, an oncology platform discovery company. As an entrepreneur-in-residence at Atlas Venture, he helped launch several portfolio companies exploring new areas of biology, including Raze Therapeutics, a next-generation cancer metabolism company, where he served as President, Founder and Director of Corporate Development. He has authored multiple peer-reviewed publications on systems biology, cell signaling, genetics and cancer biology. Dr. Friedman received his B.A. in Molecular Biology from Princeton University and received both his M.D. and Ph.D. in genetics from Harvard Medical School. Dr. Friedman trained in pediatrics at Boston Children’s Hospital.

About Scorpion Therapeutics
Scorpion Therapeutics is a next-generation Oncology company whose goal is to develop best-in-class or first-in-class precision medicines and deliver transformational outcomes for patients. To achieve this, Scorpion is applying world-leading expertise in medicinal and computational chemistry paired with chemical proteomics and latest advances in target biology to improve tumor targeting and access to previously “undruggable” targets for many cancer patients. Scorpion was named to the 2021 class of Endpoints 11, a group of the most promising up-and-coming private biotechnology companies.

Media Contact:
Ravi Moorthy
Scorpion Therapeutics

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.